| 발표일자: |
2018년 11월 2일(금) ~ 11월 4(일) |
| 발표번호: |
P(e-poster)-107 |
| 발표장소: |
코엑스 컨퍼런스룸 3층 301 A-B |
|
|
| 연령관련 황반변성에서의 안내 라니비주맙 주사술과 급성심근경색 위험성 : 환자-교차 연구 |
| 연세대학교 의과대학 안과학교실,국민건강보험 일산병원 연구소, 하버드대학교 의과대학 약물역학 및 약물경제학부, 국민건강보험 일산병원 안과 |
| 류선영, 김동욱, 김대현, 정은지 |
|
목적 : To evaluate the risk of acute myocardial infarction (AMI) development associated with intravitreal ranibizumab injection in age-related macular degeneration (AMD).
방법 : Using a retrospective cohort of patients with exudative AMD cases (n=41,860), we identified all incident AMI cases during the observation period from inpatient claims and defined the index date as the date of hospitalization. For each patient, we defined case period as 1 to 60 days before the index date and four control periods as 121 to 180, 181 to 240, 241 to 300 and 301 to 361 days. A pharmacy prescription and intravitreal injection database were searched for ranibizumab use during the case and control periods.
결과 : A total of 181 patients with AMI patients with exudative AMD were included. Of all the patients, 11.05 percent had been treated during the preceding two-month case period as compared with 8.29 to 9.39 percent during control periods. The adjusted odd ratio of AMI associated with intravitreal ranibizumab during the preceding two-month case period was 1.22 (95% confidence interval (CI) 0.673-2.213) (p=0.5124). Analyses based on risk periods of 15 days and one month yielded similar results.
결론 : Intravitreal ranibizumab injection does not appear to increase risk of hospitalization for AMI within 60 days in exudative AMD patients.
|
| |